As novel estrogen receptor modulators and degraders are needed to help patients with ER+ metastatic breast cancer, our findings suggest that activated GR could act as an ERS in the treatment of ER+ breast cancer metastasis. The gene discussed is NR3C1; the disease is breast carcinoma.